Using 3D bioprinting to accurately replicate the biological environment surrounding gastric cancer cells, researchers predicted a patient’s response to anticancer drugs during the preclinical stage.
University of Basel scientists have discovered that high levels of the amino acid arginine drive metabolic reprogramming to promote tumor growth. This could lead to improved liver cancer treatment.
Researchers from the US, Singapore and Geneva have developed a novel combination therapy using an anticancer agent for treating vancomycin-resistant Enterococcus faecalis (VRE).
The hearts of men and women are different – while this insight has been established for quite some time now, it might even surprise cardiologists just how deep these differences really run. In her presentation at this year’s ESC, Diana Bonderman, MD, gave a comprehensive roundup on sex differences in risk factors and subtypes of heart failure.
Researchers discovered that cancer cells mobilize a SOS response when they are desperate to resist anticancer drugs. The team also came up with an anti-SOS approach that blocked the mechanism in mice.
Researchers have developed an ultrasound-guided cancer immunotherapy platform that generates systemic antitumor immunity and improves the therapeutic efficacy of immune checkpoint blockade.
Latest developments in computational protein design enable the simulation of sequence and structural changes in proteins for creating novel agents in human medicine.
A major advance demonstrates first multi-organ chip made of engineered human tissues linked by vascular flow for improved modeling of systemic diseases like cancer.
New data highlights a promising new treatment for individuals with HER2-mutant non-small cell lung cancer (NSCLC).
Over the past decade, scientists have been exploring vaccination as a way to help fight cancer. These experimental cancer vaccines are designed to stimulate the body’s own immune system to destroy a tumor, by injecting fragments of cancer proteins found on the tumor.
Why do alterations of certain genes cause cancer only in specific organs of the human body? Scientists at the German Cancer Consortium (DKTK), the Technical University of Munich (TUM), and the University Medical Center Göttingen have now demonstrated that cells originating from different organs are differentially susceptible to activating mutations in cancer drivers: The same mutation in…
BOLD-100/KP1339 is a ruthenium-based anticancer agent that has been co-developed at the University of Vienna and which has shown promising results in clinical trials in cancer patients. However, the mode of action of this metal compound has not yet been fully elucidated. Researchers from the University of Vienna and the Medical University of Vienna have now been able to demonstrate that BOLD-100…
In recent years, targeted therapies have cemented their place as some of the most important tools in cancer treatment. These medicines are designed to block specific signals that tumor cells use to grow and spread, while at the same time leaving normal cells unharmed. Targeted therapies can significantly extend patients’ lives, but the benefits are often only temporary. Over time, many cancers…
Due to compromised immune systems cancer patients are at higher risk of contracting infections. How does cancer impact on patients who also contract Covid-19? To collect this data, four cancer registries, one in the EU, one in the UK, two in the USA, have been established. The first large, multi-institution study of the impact of Covid-19 was conducted in Wuhan, China, and presented at the…
A team of researchers lead by Helmholtz Zentrum München and the University of Würzburg identified an enzyme as a novel and strong inhibitor of ferroptosis, the iron dependent form of cell death: ferroptosis suppressor protein-1, short FSP1. This protein is expressed in a variety of cancer cell lines and therefore represents an attractive drug target for cancer treatment. In fact, the first FSP1…
Nanosystems that deliver anticancer drugs or imaging materials to tumours are showing significant progress, particularly those that respond to tumour-related stimuli, according to a review published in the journal Science and Technology of Advanced Materials. However, further research is still required to make sure these delivery systems are stable, non-toxic and biodegradable. Nanocarriers…
Researchers led by Professor Stefan Pfister from the "Hopp Children's Cancer Center at the NCT Heidelberg" (KiTZ) have been able to draw an extremely detailed molecular map of childhood cancers. In close collaboration with the German Cancer Consortium (DKTK) and the Society for Pediatric Oncology and Hematology (GPOH), they screened almost 1,000 tumor samples from 24 cancer types for…
A team of scientists at the Keck School of Medicine of USC is looking to some deep sea dwellers to create a better way to develop cancer-fighting therapies. Harnessing the power of the enzymes that give these marine animals the ability to glow, the team created a test that makes it easy for researchers to see whether a therapy is having its intended effect — killing cancer cells. The results of…
Patients with unresectable, or inoperable, lung cancer are often given a dismal prognosis, with low rates of survival beyond a few years. Researchers exploring combination therapies have recently discovered improved survival rates by up to one year when patients treated with a newly formulated chemotherapy regimen are also given radiation therapy.
Researchers at the Institute of Bioengineering and Nanotechnology (IBN) of A*STAR have engineered a three-dimensional heart tissue from human stem cells to test the safety and efficacy of new drugs on the heart.
A combination of a diabetes medication and an antihypertensive drug can effectively combat cancer cells. The team of researchers led by Prof. Michael Hall at the Biozentrum of the University of Basel has also reported that specific cancer cells respond to this combination of drugs.
A recent paper published in Nature Communications reveals insights about the element actinium that could support new classes of anticancer drugs. The experiment was conducted by the Department of Energy's Los Alamos National Laboratory in collaboration with the DOE's SLAC National Accelerator Laboratory.
Apart from tumour immunologists themselves, for a long time oncologists have underestimated the role of the immune system in cancer treatment. Nonetheless, in recent years increasing attention has been given to this aspect of cancer.
Cancer cells producing toxins that destroy tumours – could this be a future treatment for cancer? Researchers at Lund University have achieved good results in tests on both cells and animals. The results have now been presented in the respected scientific journal Cancer Research.
Radionuclide therapy has been rapidly developing for the last 20 years, due to the availability of new carrier molecules and radionuclides. For some years the clinical efficacy has been modest with a low percentage of objective responses and no survival benefit because, most often, the patients had large tumor burden.
Cancer can be tackled with a combination of drug and genetic therapies, so that the effectiveness of individual treatments are enhanced.